Tumor development and progression of IDH wild-type glioblastomas are highly dependent on the overexpression of RTKs involving major signaling pathways such as the EGFR/PI3K/AKT/PTEN pathway but also on the involvement of metabolic pathways. This evidence concerns the gene IDH2 and glioblastoma.